FibroBiologics, Inc. (NASDAQ: FBLG) has broadened its fibroblast‑spheroid wound‑care platform to include acute and chronic burn injuries, building on the same allogeneic technology that underpins its diabetic foot ulcer program.
Preclinical burn‑model data show a nearly four‑fold increase in tissue‑level IL‑10 and a significant reduction in IL‑1β, biomarkers linked to accelerated healing and reduced inflammation. These findings suggest the platform can create a pro‑healing environment in burn wounds.
The company is targeting a $2.55 billion global burn‑care market that is projected to grow to $3.35 billion by 2030, positioning the expansion as a strategic move to capture a sizable, underserved segment.
FibroBiologics’ CYWC628 program, already advancing toward a Phase 1/2 trial for diabetic foot ulcers, will now also be evaluated in burn patients, potentially opening new revenue streams and strengthening its competitive stance in regenerative medicine.
Financially, FibroBiologics remains a pre‑revenue, clinical‑stage company. It reported a net loss of $18.6 million for 2025 and held $4.9 million in cash as of September 30, 2025. The company has secured additional financing and received a Nasdaq Hearings Panel extension to meet listing requirements through April 2026.
"These new burn data reinforce our conviction that fibroblast spheroids can reshape how serious wounds are treated. By combining strong signals of tissue repair with meaningful reductions in inflammatory markers, CYWC628 positions us to address a large, underserved market in burn care and create significant benefit for patients. We believe that a targeted, cell‑based approach has the potential to improve healing outcomes, reduce complications, and ultimately change the standard of care for burn…" – Pete O’Heeron, Founder and CEO.
"From a scientific standpoint, seeing nearly a four‑fold increase in IL‑10 alongside a significant reduction in IL‑1β in burn tissue is highly encouraging. These tissue‑level biomarker changes align with the type of regenerative, pro‑healing environment we are aiming to create in complex wounds and give us confidence as we advance CYWC628 toward clinical development in burn patients." – Hamid Khoja, Ph.D., Chief Scientific Officer.
Investors have responded positively to the expansion, viewing it as a potential driver of future revenue growth and a reinforcement of FibroBiologics’ position in the regenerative‑medicine space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.